Table 1.
Clinical and biochemical profile
| ACS | Control | |
|---|---|---|
|
Gender (M/F) |
60/12 |
44/8 |
|
Age (years) |
63 ± 10 (42–85) |
62 ± 5 (54–73) |
|
BMI (kg/m2) |
27.5 ± 3.8 (20.6-40.8) |
27.9 ± 3.6 (21.6-40.5) |
|
WC (cm) |
101 ± 10 (70–137) |
100 ± 9 (80–118) |
|
Prevalence (%) |
|
|
|
Hypertension |
68 |
62 |
|
Dyslipidemia |
70 |
62 |
|
Type 2 Diabetes |
16 |
12 |
|
Medications (%) |
|
|
|
ACE-Inhib or ARB |
48 |
42 |
|
Ca-Channel Blocker |
18 |
20 |
|
Beta-Blockers |
44 |
38 |
|
Diuretics |
16 |
20 |
|
Statins |
34 |
30 |
|
ASA |
38 |
24 |
|
SBP (mmHg) |
131 ± 18 (95–175) |
136 ± 16 (115–165) |
|
DBP (mmHg) |
72 ± 10 (55–100) |
76 ± 6 (70–95) |
|
Creat (mg/dl) |
1.01 ± 0.28 (0.55-1.5) |
0.92 ± 0.20 (0.60-1.4) |
|
Tg (mg/dl) |
126 ± 65 (44–585) |
146 ± 35 (110–289) |
|
T-Chol (mg/dl) |
191 ± 42 (81–316) |
215 ± 41 (127–261) |
|
HDL-Chol (mg/dl) |
45 ± 8 (24–85) |
48 ± 8 (32–65) |
|
Glucose (mg/dl) |
121 ± 26 (60–221) |
114 ± 10 (86–131) |
|
Insulin (μU/ml) |
4.6 ± 2.4 (1.5-12) |
5.4 ± 3.3 (1.2-15.4) |
|
HOMA-IR |
1.45 ± 0.95 (0.3-4.8) |
1.50 ± 0.96 (0.5-3.8) |
|
CK (mU/ml) |
124 (8.4-888) |
- |
|
Troponin (ng/ml) |
14.6 (0.5-326) |
- |
|
CRP (mg/dl) |
2 (0.2-15) |
0.2 (0.02-3.1)* |
| PTX3 (ng/ml) | 5.7 (1.8-29.3) | 2.7 (1.2-5.6)* |
Gender, age, BMI, waist circumference (WC), disease prevalence, chronic medications (treatment before event for ACS); ACE-Inhib: Angiotensin Converting Enzyme-Inhibitors; ARB: Angiotensin Receptor Blockers; ASA: Acetylsalicylic Acid; systolic (SBP) and diastolic (DBP) blood pressure, plasma creatinine (creat), triglycerides (Tg), HDL cholesterol (HDL-Chol), glucose, insulin, Homeostasis Model Assessment (HOMA), plasma C-reactive protein (CRP) and pentraxin-3 (PTX3) in ACS and Control groups. Results are reported as Mean ± SD (Range) except for non-normally distributed HOMA-IR, CRP, PTX3, that are presented as Median (Range). *:P < 0.05 between ACS and Control groups by Wilcoxon test for non-normally distributed data (HOMA-IR, CRP, PTX3).